Pfaller Michael A, Jones Ronald N
Department of Pathology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Arch Pathol Lab Med. 2006 Jun;130(6):767-78. doi: 10.5858/2006-130-767-PAOAAA.
The College of American Pathologists Microbiology Surveys Program provides external proficiency samples that monitor the performance of nearly 3000 laboratories that perform and report antimicrobial susceptibility tests.
To summarize results obtained with bacterial and yeast challenge samples (2001 through 2003).
One organism every 4 months was tested by surveys participants against antibacterials/antifungals by routinely used methods. Reports were graded by interpretive category (susceptible, intermediate, resistant) based on an 80% consensus of referees/participants.
The most common antibacterial test methods/systems were Vitek (38%-43%), MicroScan (39%-43%), and the disk diffusion test (14%-15%), although Etest was most used for fastidious species. YeastOne was the dominant antifungal test (50%-55%). Antifungal results demonstrated continuous, improved accuracy (83%-88%), highest for YeastOne (96%) and broth microdilution (95%) methods. Antibacterial test accuracy was consistently greater than 97% against gram-positive organism challenges and greater than 98% against gram-negative challenges. For gram-negative strains with well-characterized resistance mechanisms, the accuracy by method was disk diffusion greater than broth microdilution greater than automated systems. Major problems identified were (1) Haemophilus influenzae control ranges require re-evaluation, (2) overuse of beta-lactamase tests, (3) errors among Enterococcus faecium against penicillins (Vitek 2, MicroScan), (4) false-susceptible results with trimethoprim/sulfamethoxazole against coagulase-negative staphylococci (MicroScan), (5) macrolide false-susceptibility for beta-hemolytic streptococcus (MicroScan), (6) flawed reporting for antimicrobials not active at the infection site, (7) use of outdated interpretive criteria, and (8) failure to follow Clinical and Laboratory Standards Institute testing/reporting recommendations.
Susceptibility tests were generally performing satisfactorily as measured by the surveys, but serious errors were identified with some drug/organism combinations that may require action by the Clinical and Laboratory Standards Institute and/or the Food and Drug Administration.
美国病理学家学会微生物学调查项目提供外部能力验证样本,以监测近3000家进行并报告抗菌药物敏感性试验的实验室的表现。
总结2001年至2003年期间细菌和酵母菌挑战样本的检测结果。
调查参与者每隔4个月使用常规方法对一种生物体进行抗菌药物/抗真菌药物检测。报告根据裁判/参与者80%的共识,按照解释类别(敏感、中介、耐药)进行分级。
最常用的抗菌检测方法/系统是Vitek(38%-43%)、MicroScan(39%-43%)和纸片扩散法(14%-15%),不过Etest最常用于苛养菌。YeastOne是主要的抗真菌检测方法(50%-55%)。抗真菌检测结果显示准确性持续提高(83%-88%),YeastOne方法(96%)和肉汤微量稀释法(95%)的准确性最高。针对革兰氏阳性菌挑战,抗菌检测准确性始终高于97%;针对革兰氏阴性菌挑战,准确性高于98%。对于具有明确耐药机制的革兰氏阴性菌株,各方法的准确性为纸片扩散法>肉汤微量稀释法>自动化系统。发现的主要问题有:(1)流感嗜血杆菌的质控范围需要重新评估;(2)β-内酰胺酶检测使用过度;(3)屎肠球菌对青霉素(Vitek 2、MicroScan)检测出现误差;(4)甲氧苄啶/磺胺甲恶唑对凝固酶阴性葡萄球菌检测出现假敏感结果(MicroScan);(5)β-溶血性链球菌对大环内酯类药物检测出现假敏感结果(MicroScan);(6)对在感染部位无活性的抗菌药物报告存在缺陷;(7)使用过时的解释标准;(8)未遵循临床和实验室标准协会的检测/报告建议。
根据调查衡量,药敏试验总体表现令人满意,但发现一些药物/生物体组合存在严重误差,临床和实验室标准协会及/或食品药品管理局可能需要采取行动。